Investors / United States / InVivium Capital
InVivium Capital
Venture capital · Chicago, IL, United States · North America
InVivium Capital is a venture capital fund focused on investments in healthcare and life sciences. It invests across the spectrum of healthcare innovation, primarily biotechnology and medical devices, and partners with seed and venture development programs to build relationships from seed through later growth stages.
Invests inHealthcare & Biotech
In its own wordshealthcarelife sciencesbiotechnologymedical devicestherapeutics
Your fit with InVivium Capital
Four questions about your startup
See how your round matches what it backs, point by point.
Or find every investor that fitsInVivium Capital lists 7 checked portfolio companies on its own site and is named in 1 funding round, 1 of them as lead. Its most frequent entry is Series A, 100% of the companies with a known first round. Its largest theme is Healthcare & Biotech (100%). 100% of its companies are based in United States. It invests most often alongside Able Partners, Agent Capital and Arboretum Ventures.
Counts come from funding rounds that name InVivium Capital, complete from mid-2025: earlier rounds appear only when they were reported later. Round amounts and full round histories are on Fundup AI.
Entry stage
share of companies by the stage of its first roundShow as a table
| Value | |
|---|---|
| Pre-seed | 0% |
| Seed | 0% |
| Series A | 100% |
| Series B | 0% |
| Growth | 0% |
Activity by year
rounds it joined, last 10 yearsShow as a table
| Total | Rounds it led | |
|---|---|---|
| '17 | 0 | 0 |
| '18 | 0 | 0 |
| '19 | 0 | 0 |
| '20 | 0 | 0 |
| '21 | 0 | 0 |
| '22 | 0 | 0 |
| '23 | 0 | 0 |
| '24 | 0 | 0 |
| '25 | 1 | 1 |
| '26 | 0 | 0 |
Investor profile
percentile among all firmsShow as a table
| Measure | Percentile of all firms | Value |
|---|---|---|
| Portfolio size | 12th | 7 companies |
| Recent activity | 46th | 0 rounds in 12 months |
| Early stage | 54th | 0% of entries at pre-seed or seed |
| Evidence | 85th | 14% of companies confirmed by a round |
| Sector focus | 100th | 100% in its largest sector |
| Reach | 19th | 1 country |
Invests most often with
firms sharing its portfolio companiesShow as a table
| Share | |
|---|---|
| Able Partners | 1 |
| Agent Capital | 1 |
| Arboretum Ventures | 1 |
| Catalio Capital Management | 1 |
| DCVC | 1 |
| DeepWork Capital | 1 |
| F-Prime Capital | 1 |
| Global Source Ventures | 1 |
Its portfolio companies
where they are based, and what their own sites showSite status
- Site answers7100%
- No longer answers00%
- Points to another company00%
- Parked or sold domain00%
A site that stops answering three checks in a row is counted as no longer answering; that is not proof of closure. A site that points to another company is often an acquisition.
Investment themes
share of its checked companiesThis firmAll checked companies
Show as a table
| This firm | All checked companies | |
|---|---|---|
| Healthcare & Biotech | 100% | 15% |
Co-investor network
who it backs companies with, and who they back togetherCompare InVivium Capital head to head
portfolio size, rounds, entry stages, themes and the companies both backThree or more firms at once: portfolio overlap.
Recent portfolio activity
when companies last raised with InVivium Capital| Date | Company | Stage |
|---|---|---|
| 7 Nov 2025 | Series A Led |
Round details for InVivium Capital
Amounts, full round histories and every co-investor in InVivium Capital's rounds are on Fundup AI. VCinfo covers investors and their portfolios.
Portfolio
7 companies checked against their own sites| Company | What it does | Themes | First round with it | Evidence |
|---|---|---|---|---|
| Alto Neuroscience develops biology-driven medicines for neuropsychiatric conditions | Healthcare & Biotech | Portfolio page | ||
| Avalyn Pharma develops inhaled therapies to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases. | Healthcare & Biotech | Portfolio page | ||
| Grove Biopharma is pioneering Bionic Biologics, a breakthrough synthetic modality for developing novel therapeutics that target intracellular protein-protein interactions. | Healthcare & Biotech | Portfolio page | ||
| Hinge Bio develops next-generation therapeutics for difficult to treat diseases | Healthcare & Biotech | Portfolio page | ||
| Onchilles Pharma is a clinical-stage biotechnology company pioneering first-in-class cytotoxic therapies designed to selectively kill cancer cells while preserving and activating immune function. | Healthcare & Biotech | Nov 2025Series A | Page + round | |
| Revelyx Bio develops and commercializes biopharmaceutical products, including an investigational recombinant botulinum toxin type A | Healthcare & Biotech | Portfolio page | ||
| Virtual Incision develops and introduces a miniaturized robotic-assisted surgery system | Healthcare & Biotech | Portfolio page |
About this data
site last read 5 Nov 2026- Site
- invivium.com
- Last read
- 5 Nov 2026
- Watching since
- 5 Nov 2026
- Rounds since
- 7 Nov 2025
- Companies checked
- 7
Rates come from what VCinfo has observed since observation_start. Firms tend to remove companies that closed, so early rates understate reality. A company leaving a portfolio page does not mean it closed or exited. An unreachable site means our checks failed, nothing more.
Get InVivium Capital's profile as data
Pull InVivium Capital's portfolio, co-investors and changes through one API key or MCP, open every portfolio row, compare it with other firms, and get an email when it adds a company or files a fund.
Work email, sign-in link by email. Already have an account? Log in- Ask AI5 plain-English investor searches a day
- Full listsEvery portfolio row and two-firm overlap
- API and MCP100 REST or MCP calls a month, one key
- AlertsFollow 5 investors for portfolio and fund changes
$ curl -H "X-API-Key: YOUR_KEY" \
https://api.vcinfo.io/v1/firms/invivium.com
# also
GET /v1/firms/invivium.com/portfolio
GET /v1/firms/invivium.com/coinvestors
GET /v1/firms/invivium.com/news